

July 20, 1999

To the FDA:

6915 '99 JUL 22 P2:11

RE: DOCKET NO 98N-1265

As one who cannot tolerate certain patented drugs I would be severely and adversely affected by the MOU as currently written.


Why do you propose to treat compounded drugs differently than noncompounded drugs? Equal treatment under the law is called for allowing the consumer along with his/her physician to decide what is best for their health.

As a healthcare consumer, there should be no restrictions ^{to} the delivery of a compounded medication prescribed for me, regardless of where I may live or travel. The MOU must be amended!

Sincerely,
Betty T. Felder

98N-1265

C4314



Dockets Management Branch (HFA-305)
Food & Drug Administration
5630 Fishers Lane, Room 1061
Rockville, MD. 20857-0003



B.T. Falden
659 Omar Circle
Yellow Springs, Ohio
45387
